Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
To assess the association between vitamin D-Binding Protein (VDBP rs7041T>G) and vitamin D receptor (VDR rs1544410G>A) gene polymorphisms with susceptibility to cardiovascular diseases in population from west of Iran.
|
31359379 |
2019 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Allele frequency and genotype distribution were analyzed between CVD patients and control subjects, and haplotype analysis was used to evaluate the combined effect of VDR SNPs on CVD pathogenesis.
|
30683435 |
2019 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
VDR has been shown to be involved in cardiovascular diseases, cancer, autoimmunity and type 2 diabetes mellitus (T2DM).
|
27052925 |
2016 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Vitamin D receptor (VDR) is a potential candidate for cardiovascular disease.
|
25498546 |
2015 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Vitamin D receptor polymorphism in chronic kidney disease patients with complicated cardiovascular disease.
|
25499229 |
2015 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Interactions between two previously studied VDR polymorphisms (rs7968585 and rs2239179) and 25OHD concentrations on metabolic and cardiovascular disease-related outcomes such as obesity- (body mass index, waist circumference, waist-hip ratio (WHR)), cardiovascular- (systolic and diastolic blood pressure), lipid- (high- and low-density lipoprotein, triglycerides, total cholesterol), inflammatory- (C-reactive protein, fibrinogen, insulin growth factor-1, tissue plasminogen activator) and diabetes- (glycated haemoglobin) related markers were examined in the 1958 British Birth cohort (n up to 5160).
|
24582179 |
2014 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
These results suggest that endothelial VDR plays an important role in endothelial cell function and blood pressure control and imply a potential role for VDR agonists in the management of cardiovascular disease associated with endothelial dysfunction.
|
25201890 |
2014 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The aim of this work was to evaluate whether the FokI and BsmI polymorphisms of the VDR gene are associated with anthropometric and biochemical features of cardiovascular disease (CVD) in a Caucasian population aged over 65, participants of the Polish PolSenior study.
|
23173643 |
2013 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
VDR-knockout mice suffer from cardiovascular disease (CVD), and various experimental studies suggest cardiovascular protection by vitamin D, including antiatherosclerotic, anti-inflammatory and direct cardio-protective actions, beneficial effects on classic cardiovascular risk factors as well as suppression of parathyroid hormone (PTH) levels.
|
21682758 |
2011 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Whether treatment with vitamin D receptor activators contributes to cardiovascular disease in patients with chronic kidney disease is a matter of debate.
|
21063202 |
2011 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
These results identify reduced vitamin D receptor signaling as a potential mechanism underlying increased foam cell formation and accelerated cardiovascular disease in diabetic subjects.
|
19667238 |
2009 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
LHGDN |
These results suggest that the Vitamin D Receptor alleles b, a, T could be considered novel risk factors in the pathogenesis of inflammation-related, atherosclerosis-dependent cardiovascular disease risk in uremic patients.
|
18491455 |
2008 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
Selective VDR ligands, in particular, may offer additional benefits in the treatment of bone disease, and may potentially reduce adverse effects related to cardiovascular disease.
|
18826852 |
2008 |
Cardiovascular Diseases
|
0.200 |
Biomarker
|
group |
BEFREE |
The regulation of NPR-A may be one of several mechanisms by which VDR activation reduces CVD risk in CKD.
|
17653231 |
2007 |
Cardiovascular Diseases
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Our findings support the hypothesis that smoking-related DNA damage may be involved in the onset of cardiovascular diseases and suggest that VDR genotype may be a useful susceptibility marker of CAD.
|
9761785 |
1998 |